European Lung Cancer Congress 2025: Abstracts

The ELCC 2025 abstract submission is now open

Submit your abstract

Abstract submission deadlines 

Outcome notifications

Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by early February.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end February.

Submission categories

• Tumour biology and pathology
• Translational research
• Prevention, early detection, epidemiology, tobacco control
• Imaging and staging
• SCLC
• Early stage NSCLC
• Locally advanced NSCLC
• Advanced NSCLC
• Metastases to and from the lung
• Mesothelioma
• General interest

Late-breaking abstracts (LBA) 

Late-breaking abstracts may be submitted for high quality, new research findings from prospective interventional clinical trials or observational series (large real-world data sets) or novel technologies with major implications for clinical practice and/or understanding and targeting of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 January 2025 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ELCC 2025.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline of Tuesday, 14 January 2025.   

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by Tuesday, 18 February 2025. 

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2025.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

1. Background
2. Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 14 January 2025.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
• Encore TiP abstracts will NOT be accepted.

Publication schedule for accepted abstracts

Details regarding the publication of accepted abstracts are available here.

Details regarding ESMO PR activities will be made available 10 days prior to the Congress.

Embargo policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Presentation and publication of accepted abstracts 

The ELCC 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper: Oral presentation of original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral: Short oral presentation of good quality data, followed by expert discussion and perspectives.
• Poster: Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts will be published in the ELCC 2025 Abstract Book, a supplement of the official IASLC journal, Journal of Thoracic Oncology.